HAVANA, (Reuters) - Cuba said yesterday its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2% effective in late stage clinical trials against the coronavirus, following similar news about its Abdala vaccine.
The article Cuba says second COVID-19 vaccine Soberana 2 boasts 91.2% efficacy appeared first on Stabroek News.
